140 116

Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group

Authors
 Hyo Sup Shim  ;  Jin-Haeng Chung  ;  Lucia Kim  ;  Sunhee Chang  ;  Wan-Seop Kim  ;  Geon Kook Lee  ;  Soon-Hee Jung  ;  Se Jin Jang 
Citation
 Korean Journal of Pathology, Vol.47(2) : 100-106, 2013 
Journal Title
 Korean Journal of Pathology 
ISSN
 1738-1843 
Issue Date
2013
Abstract
Mutations of the epidermal growth factor receptor (EGFR) are the strongest predictive factor for response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. EGFR TKIs are approved in Korea as a first-line treatment for lung cancer patients with mutated EGFR. Rapid and accurate EGFR mutation testing is essential for patient selection and establishing targeted therapies with EGFR TKIs. Thus, a standard set of guideline recommendations for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of guideline recommendations for EGFR mutation testing that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/86653
Files in This Item:
T201300887.pdf Download
DOI
10.4132/KoreanJPathol.2013.47.2.100
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실)
Yonsei Authors
심효섭(Shim, Hyo Sup) ORCID logo https://orcid.org/0000-0002-5718-3624
Export
RIS (EndNote)
XLS (Excel)
XML
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse